Abstract Library

#3560 Nutritional status in patients with neuroendocrine tumors: A single ENETS Centre of Excellence experience

Introduction: Studies show that 14–68% of patients with neuroendocrine tumors (NETS) are at risk of or are malnourished. Patients’ dependent on NET type, primary or treatment are at risk of Vitamin B12, A, D E, iron deficiencies, pancreatic enzyme insufficiency (PEI) and a high HbA1c.

Conference:

Presenting Author:

Authors: Burke D, Almeamar H, O'Toole D, Barnes L, Crowley R,

Keywords: malnutrition, deficiencies, Pancreatic enzyme insufficiency, HbA1c's,

#2819 Occurrence of Pancreatic Exocrine Insufficiency in Patients with Advanced Neuroendocrine Tumours Treated with Somatostatin Analogue

Introduction: Neuroendocrine neoplasia (NENs) are heterogeneous tumours caracterized by a relatively indolent rate of growth. Usually, in G1 and G2 GEP-NENs, first-line therapy is SSAs, considering their efficacy, good safety profile, and antiproliferative effects. SSA treatment inhibits the production and excretion of pancreatic enzymes and PEI is known to be an adverse effect of SSA treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Rinzivillo M

Authors: De Felice I, Rinzivillo M, Pratesi M, Magi L, Annibale B,

Keywords: Pancreatic Exocrine Insufficiency,

#2776 The Effects of Somatostatin Analogues on HbA1c and BMI in the Treatment of Neuroendocrine Tumours

Introduction: Long acting somatostatin analogues (SSA) are the most commonly used drugs in the management of neuroendocrine tumours (NETs) due to their ability to control symptoms and prolong survival. SSAs use is associated with changes in glucose metabolism. However, there is lack of data for such effects in patients with NETs. We evaluated the effects of SSA on BMI and HbA1c in our cohort of patients with NETs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Patel K

Authors: Patel K, Nahar A, Elhassan Y, Shah T, Ayuk J,

Keywords: Somatostatin analogues, Diabetes, Neuroendocrine tumour, HbA1c, BMI,

#2284 The Association between Gastrin and Glucose Serum Concentration in Hypergastrinemic Patients with Gastric Neuroendocrine Tumors Type 1 and ECL-Cells Hyperplasia

Introduction: There is previous data demonstrating that elevated gastrin levels could exert some effect potentiating the glucose-induced insulin secretion.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Mavroeidi V

Authors: Moschouris P, Mavroeidi V, Nikolopoulos G, Tsoli M, Karapanagioti A,

Keywords: Gastric Neuroendocrine Tumors Type 1, ECL-Cells Hyperplasia, gastrin, glucose,

#1145 The Association Between Gastrin and Glucose Serum Concentration

Introduction: Gastrin is an early incretin candidate, since it is released by oral glucose and potentiates the glucose- induced insulin secretion. It has been shown that only in hypoglycemic or hyperglycemic conditions gastrin release is influenced by changes in blood glucose and insulin concentrations.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Boutzios G

Authors: Boutzios G, Alexandraki K, Moschouris P, Chatzellis E, Evaggelatou A,

Keywords: gastrin levels, glucose levels, HbA1c,